Replimune Raises $55 Million to Advance its Oncolytic Immunotherapy Programs

WOBURN, Massachusetts, September 8, 2017 -- (Healthcare Sales & Marketing Network) -- Replimune Group Inc., a biotechnology company focused on developing next generation oncolytic immunotherapies, announced today the completion of a $55 million Series B f... Biopharmaceuticals, Oncology, Venture Capital Replimune Group, Immulytic , oncolytic immunotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news